Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> MutationBella Kaufman, Susan M. Domchek, Ronnie Shapira‐Frommer et al.|Journal of Clinical Oncology|2014Cited by 1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialAndrew Tutt, James Carmichael, Mark E. Robson et al.|The Lancet|2010Cited by 1.6k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study GroupKathryn Alsop, Gillian Mitchell, Sián Fereday et al.|Journal of Clinical Oncology|2012Cited by 1.2k
Association of Type and Location of<i>BRCA1</i>and<i>BRCA2</i>Mutations With Risk of Breast and Ovarian CancerTimothy R. Rebbeck, Saundra S. Buys, Sylvie Mazoyer et al.|JAMA|2015Cited by 507
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian CancerSusan J. Ramus, Simon A. Gayther, Honglin Song et al.|JNCI Journal of the National Cancer Institute|2015Cited by 441